Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative, minimally systemic therapeutic agents that work exclusively in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The company was founded in 2007 and is headquartered in Fremont, California.